Gulfstream Daily Brief

Regulatory intelligence and policy · Issue 041

FDA advances genome editing and IDE submission guidance

FDA published two notable draft guidances, covering individualized genome editing products and electronic IDE submissions. EMA and MHRA also updated guidance and regulatory information.

By Scott Morvay, Founder October 28, 2026 Official sources linked

FDA

FDA proposes a BLA framework for individualized genome editing products

Draft guidance provides recommendations for submitting multiple product variants in one BLA, defining component variation, and adding variants after licensure. It is not final or ready for implementation.

Read the official source

FDA

FDA introduces draft guidance for electronic IDE submissions

The draft directs sponsors submitting IDE applications to CDRH and CBER to current resources supporting electronic submissions. FDA intends the future template to improve submission consistency and review efficiency.

Read the official source

FDA

FDA opens comment on electronic records and signatures information collection

FDA is seeking public comment on information collection applicable to electronic record and signature provisions in its regulations, with a 60 day comment period under the Paperwork Reduction Act.

Read the official source

EMA

EMA publishes tofacitinib product specific bioequivalence guidance

EMA issued product specific bioequivalence guidance for tofacitinib 11 mg prolonged-release tablets, reference EMA/200335/2026.

Read the official source

MHRA

MHRA updates access to work sharing initiatives

MHRA provided information on applying for New Active Substance and Biosimilar Work Sharing Initiative assessments, together with a list of approved products.

Read the official source

MHRA

MHRA updates performance and regulatory timeline data

MHRA published KPI performance data and information on expected timelines for completing specific regulatory functions.

Read the official source

Why this matters

The FDA drafts address two evolving submission models: managing variant based genome editing products within a BLA and standardizing electronic IDE preparation. The EMA and MHRA updates add practical reference points for bioequivalence, work sharing routes, and regulatory timelines. Regulatory teams should distinguish draft FDA thinking from final requirements and review the open electronic records comment opportunity.

Scott Morvay

Founder, Gulfstream Intelligence

This brief provides general regulatory news and educational information. It is not legal or regulatory advice.